ライフサイエンスコーパス: pulmonary aspergillosis

1 ill UK patients with COVID-19 and suspected pulmonary aspergillosis.

2 f A. terreus to AmB in experimental invasive pulmonary aspergillosis.

3 ent a new strategy for treatment of invasive pulmonary aspergillosis.

4 d animals against subsequent lethal invasive pulmonary aspergillosis.

5 ay key roles in host defense against primary pulmonary aspergillosis.

6 important proximal signal in murine invasive pulmonary aspergillosis.

7 ses susceptibility to postinfluenza invasive pulmonary aspergillosis.

8 There was one transplant-related death from pulmonary aspergillosis.

9 th was the predominant histologic pattern of pulmonary aspergillosis.

10 an immunosuppressed murine model of invasive pulmonary aspergillosis.

11 influenza virus-infected mice from invasive pulmonary aspergillosis.

12 s associated with susceptibility to invasive pulmonary aspergillosis.

13 as associated with the incidence of invasive pulmonary aspergillosis.

14 iation between severe influenza and invasive pulmonary aspergillosis.

15 and in a neutropenic mouse model of invasive pulmonary aspergillosis.

16 d A. fumigatus avirulent in a mouse model of pulmonary aspergillosis.

17 idia either in vitro or in a murine model of pulmonary aspergillosis.

18 als for comprehension of the pathogenesis of pulmonary aspergillosis.

19 s is the causative agent of allergic broncho-pulmonary aspergillosis.

20 , and the remaining 165 patients no invasive pulmonary aspergillosis.

21 d is avirulent in a murine model of invasive pulmonary aspergillosis.

22 tic cell transplant recipients with invasive pulmonary aspergillosis.

23 osuppressed mice from experimentally induced pulmonary aspergillosis.

24 nt in two distinct murine models of invasive pulmonary aspergillosis.

25 of haematogenously disseminated and invasive pulmonary aspergillosis.

26 ion in vitro and in mouse models of invasive pulmonary aspergillosis.

27 be antagonistic in the treatment of invasive pulmonary aspergillosis.

28 ung tissue recovered from mice with invasive pulmonary aspergillosis.

29 -mediated pH response in the pathogenesis of pulmonary aspergillosis.

30 t (n = 524), 79 patients had proven invasive pulmonary aspergillosis (15.1%).

31 2(-/-) mice displayed high susceptibility to pulmonary aspergillosis, a phenotype associated with a p

32 f critically ill patients, putative invasive pulmonary aspergillosis according to AspICU algorithm wa

33 Chronic pulmonary aspergillosis adds about 3,200 cases each year

34 We evaluated the incidence of invasive pulmonary aspergillosis among intubated patients with cr

35 study we evaluated the incidence of invasive pulmonary aspergillosis among intubated patients with cr

36 etermining BAL GM levels in the diagnosis of pulmonary aspergillosis among nonimmunocompromised hosts

37 .9%, likely reflecting the low prevalence of pulmonary aspergillosis among nonimmunosuppressed patien

38 Incidences of invasive pulmonary aspergillosis, an infection caused predominant

39 ions include invasive aspergillosis, chronic pulmonary aspergillosis and bronchitis.

40 covered as the etiological agent of invasive pulmonary aspergillosis and had reduced in vitro suscept

41 plored targets for the treatment of invasive pulmonary aspergillosis and may potentiate both innate i

42 In noncancer populations, both invasive pulmonary aspergillosis and mucormycosis are associated

43 Intensive Care Medicine influenza-associated pulmonary aspergillosis and the European Confederation o

44 is known about the pathogenesis of invasive pulmonary aspergillosis and the relationship between the

45 ally successful if initiated early, although pulmonary aspergillosis and zygomycosis are portentous a

46 pulmonary aspergillosis, chronic necrotizing pulmonary aspergillosis, and aspergilloma.

47 at the inflammatory response during invasive pulmonary aspergillosis, and in particular the IL-1 axis

48 This is particularly true for invasive pulmonary aspergillosis, as so far, sources of (macro)el

49 n of neutrophils, animals developed invasive pulmonary aspergillosis, associated with delayed influx

50 (n=4880 certificates); specifically, 'other pulmonary aspergillosis' (B44.1, n=4292).

51 e diagnosed with putative or proven invasive pulmonary aspergillosis, based on the validated AspICU a

52 Reaching a consensual definition of invasive pulmonary aspergillosis becomes mandatory and confers fu

53 c fibrosis patients without allergic broncho-pulmonary aspergillosis but sensitized to A. fumigatus a

54 es were classified as coronavirus-associated pulmonary aspergillosis (CAPA) according to previous con

55 es were classified as coronavirus associated pulmonary aspergillosis (CAPA) according to previous con

56 The literature regarding COVID-19-associated pulmonary aspergillosis (CAPA) has shown conflicting obs

57 or coronavirus disease (COVID-19)-associated pulmonary aspergillosis (CAPA) has yet to be explored.

58 ronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is a frequent superinfect

59 COVID-19-associated pulmonary aspergillosis (CAPA) is typically diagnosed on

60 ronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) occurs in critically ill

61 pectively classified for COVID-19-associated pulmonary aspergillosis (CAPA) status following the 2020

62 COVID-19-associated pulmonary aspergillosis (CAPA) was recently reported as

63 9 (COVID-19) may develop COVID-19-associated pulmonary aspergillosis (CAPA), which impacts their chan

64 is, including those with COVID-19-associated pulmonary aspergillosis (CAPA), which in its early stage

65 The increased incidence of invasive pulmonary aspergillosis, caused by Aspergillus fumigatus

66 Invasive pulmonary aspergillosis causes substantial mortality in

67 spergillus fumigatus causes chronic cavitary pulmonary aspergillosis (CCPA) and allergic bronchopulmo

68 aspergillosis, two each with acute invasive pulmonary aspergillosis, chronic necrotizing pulmonary a

69 vitro, could account for chronic necrotizing pulmonary aspergillosis (CNPA), which is seen most commo

70 From 2014-2019, invasive pulmonary aspergillosis complicated 7.2% (0-23.1% in dif

71 Animal Mycology (ISHAM) COVID-19-associated pulmonary aspergillosis consensus criteria.

72 Immune defects in chronic pulmonary aspergillosis (CPA) are poorly characterized.

73 Chronic pulmonary aspergillosis (CPA) is a progressive fungal di

74 Chronic pulmonary aspergillosis (CPA) is an infectious disease t

75 ) in assessing treatment response in chronic pulmonary aspergillosis (CPA) remains to be determined.

76 Chronic pulmonary aspergillosis (CPA) usually develops in patien

77 ecific IgG is critical to diagnosing chronic pulmonary aspergillosis (CPA).

78 body improves survival of mice with invasive pulmonary aspergillosis, demonstrating the potential of

79 -associated and 6 proven COVID-19-associated pulmonary aspergillosis diagnoses were identified.

80 Conclusions: A proven invasive pulmonary aspergillosis diagnosis was found regularly an

81 In invasive pulmonary aspergillosis, direct invasion and occlusion o

82 Asp f 6 helped distinguish allergic broncho-pulmonary aspergillosis from A. fumigatus sensitization

83 ill patients with influenza associated with pulmonary aspergillosis from three hospital ICUs between

84 Blood from three patients with pulmonary aspergillosis had positive PCR results: one pa

85 Rationale: Invasive pulmonary aspergillosis has emerged as a frequent coinfe

86 ecruitment in neutropenic mice with invasive pulmonary aspergillosis (IA).

87 Influenza-associated pulmonary aspergillosis (IAPA) is a feared complication

88 Influenza-associated pulmonary aspergillosis (IAPA) is a severe fungal superi

89 Influenza-associated pulmonary aspergillosis (IAPA) is a significant fungal c

90 ogens, in patients with influenza-associated pulmonary aspergillosis (IAPA) or coronavirus disease (C

91 detecting galactomannan (GM) for diagnosing pulmonary aspergillosis in 73 nonimmunocompromised patie

92 tunistic fungal pathogen and causes invasive pulmonary aspergillosis in conditions with compromised i

93 By use of a model of invasive pulmonary aspergillosis in corticosteroid-treated CF-1 m

94 respiratory tract colonization from invasive pulmonary aspergillosis in critically ill patients.

95 Therefore, we evaluated susceptibility to pulmonary aspergillosis in globally NADPH oxidase-defici

96 ives: We investigated the invasive nature of pulmonary aspergillosis in histology specimens of influe

97 was assessed using a murine model of primary pulmonary aspergillosis in immunocompetent Crl:CF-1 mice

98 us is an important pathogen causing invasive pulmonary aspergillosis in immunocompromised patients.

99 ungal clearance during experimental invasive pulmonary aspergillosis in neutropenic mice.

100 Pulmonary aspergillosis in nonimmunocompromised hosts, a

101 (LFA) with automated reader for diagnosis of pulmonary aspergillosis in patients with COVID-19-associ

102 tion triazole, against experimental invasive pulmonary aspergillosis in persistently neutropenic rabb

103 ultaneous treatment of experimental invasive pulmonary aspergillosis in persistently neutropenic rabb

104 undamental insights into the pathogenesis of pulmonary aspergillosis in the immunocompromised host.

105 ergillus colonization from putative invasive pulmonary aspergillosis in this patient group.

106 ncommon but severe clinical form of invasive pulmonary aspergillosis in which the fungal infection is

107 literature related to diagnosis of invasive pulmonary aspergillosis, invasive candidiasis, and the c

108 Risk factors for invasive pulmonary aspergillosis (IPA) after kidney transplantati

109 tic factors and optimal therapy for invasive pulmonary aspergillosis (IPA) after kidney transplantati

110 age (BAL) fluid in the diagnosis of invasive pulmonary aspergillosis (IPA) among solid-organ transpla

111 al setting, is highly suggestive of invasive pulmonary aspergillosis (IPA) and associated with specif

112 kemia during the study period, with invasive pulmonary aspergillosis (IPA) complicating 6.8% of ISA,

113 gal therapy on an LFD developed for invasive pulmonary aspergillosis (IPA) detection.

114 Invasive pulmonary aspergillosis (IPA) has dire consequences in h

115 Diagnosing invasive pulmonary aspergillosis (IPA) in non-immunosuppressed pa

116 Invasive pulmonary aspergillosis (IPA) is a frequently fatal infe

117 Invasive pulmonary aspergillosis (IPA) is a life-threatening dise

118 Invasive pulmonary aspergillosis (IPA) is a life-threatening lung

119 Invasive pulmonary aspergillosis (IPA) is a life-threatening lung

120 Invasive pulmonary aspergillosis (IPA) is a significant cause of

121 Invasive pulmonary aspergillosis (IPA) is a significant complicat

122 e to unresolved inflammation during invasive pulmonary aspergillosis (IPA) is associated with a poor

123 Invasive pulmonary aspergillosis (IPA) is frequent and often fata

124 Invasive pulmonary aspergillosis (IPA) is often a lethal entity i

125 Invasive pulmonary aspergillosis (IPA) is one of the major compli

126 cation of the causative organism in invasive pulmonary aspergillosis (IPA) is recommended.

127 Invasive pulmonary aspergillosis (IPA) is the most common manifes

128 Diagnosis of invasive pulmonary aspergillosis (IPA) remains a major challenge

129 Invasive pulmonary aspergillosis (IPA) remains an important cause

130 stem cell transplant recipients to invasive pulmonary aspergillosis (IPA), as correct levels of pers

131 Invasive pulmonary aspergillosis (IPA), once limited to immunocom

132 ncluding 20 with probable or proven invasive pulmonary aspergillosis (IPA), seven with mucormycosis,

133 ynamics of caspofungin (CAS) during invasive pulmonary aspergillosis (IPA).

134 patients, typically manifesting as invasive pulmonary aspergillosis (IPA).

135 a major role in the development of invasive pulmonary aspergillosis (IPA).

136 ontribute to therapeutic failure in invasive pulmonary aspergillosis (IPA).

137 e gold standard test for diagnosing invasive pulmonary aspergillosis (IPA).

138 n antifungal immunity in a model of invasive pulmonary aspergillosis (IPA).

139 rst-line agent for the treatment of invasive pulmonary aspergillosis (IPA).

140 y facilitate the early diagnosis of invasive pulmonary aspergillosis (IPA).

141 aluation of patients with suspected invasive pulmonary aspergillosis (IPA).

142 Invasive pulmonary aspergillosis is a common and devastating comp

143 Invasive pulmonary aspergillosis is a devastating complication of

144 Invasive pulmonary aspergillosis is a devastating complication of

145 Invasive pulmonary aspergillosis is a leading cause of infection-

146 Invasive pulmonary Aspergillosis is a leading cause of morbidity

147 Pulmonary aspergillosis is a lethal mold infection in th

148 Invasive pulmonary aspergillosis is acquired through inhalation o

149 Invasive pulmonary aspergillosis is an emerging devastating infec

150 Invasive pulmonary aspergillosis is an important cause of morbidi

151 The diagnosis of pulmonary aspergillosis is difficult, since the recovery

152 mononuclear cells into the lung in invasive pulmonary aspergillosis is in part mediated by MIP-1 alp

153 rs, and antifungal drug therapy for invasive pulmonary aspergillosis may be further understood.

154 otein 1 (PD-1) blockade in a murine invasive pulmonary aspergillosis model.

155 nd in situ angiogenesis in a murine invasive pulmonary aspergillosis model.

156 ced mutant was hypervirulent in the invasive pulmonary aspergillosis murine model system and showed i

157 pulmonary aspergillosis, chronic necrotizing pulmonary aspergillosis, or invasive aspergillosis (IA),

158 ngal lung burdens in a rat model of invasive pulmonary aspergillosis (p<0.05) compared to treatment w

159 , in a separate cohort of confirmed invasive pulmonary aspergillosis patients, polymorphisms in the I

160 finition was compared with putative invasive pulmonary aspergillosis (PIPA).

161 in patients with proven or probable invasive pulmonary aspergillosis, should combination therapy with

162 in patients with proven or probable invasive pulmonary aspergillosis, should combination therapy with

163 kely to serve as an S source during invasive pulmonary aspergillosis since a sulfate transporter muta

164 the role of PCR in the diagnosis of invasive pulmonary aspergillosis, the role of beta-d-glucan assay

165 um and BAL and for the diagnosis of invasive pulmonary aspergillosis, the role of PCR in the diagnosi

166 is associated with poor outcome to invasive pulmonary aspergillosis, this suggested that IFNAR2 may

167 or patients with proven or probable invasive pulmonary aspergillosis to receive either initial combin

168 or patients with proven or probable invasive pulmonary aspergillosis to receive either initial combin

169 s and in nine patients with allergic broncho-pulmonary aspergillosis (two with cystic fibrosis and se

170 Six patients had pulmonary aspergillosis, two each with acute invasive pu

171 iagnosis of probable/proven viral-associated pulmonary aspergillosis (VAPA) was made based on the Int

172 Invasive pulmonary aspergillosis was an independent risk factor f

173 Invasive pulmonary aspergillosis was defined according to Europea

174 Probable or proven invasive pulmonary aspergillosis was diagnosed in 14% of our stud

175 l alkalinization in the host defense against pulmonary aspergillosis, we observed high morbidity of p

176 dmitted to the ICU with severe influenza and pulmonary aspergillosis were included.

177 environmental fungus that can cause invasive pulmonary aspergillosis when spores are inhaled into the

178 piratory disease, and postinfluenza invasive pulmonary aspergillosis, which is becoming a well-recogn

179 ts underwent screening protocol for invasive pulmonary aspergillosis with bronchoalveolar lavage gala

180 underwent a screening protocol for invasive pulmonary aspergillosis with bronchoalveolar lavage gala

181 3-beta-d-glucan concentrations than invasive pulmonary aspergillosis without tracheobronchial lesions

182 s between tracheobronchial aspergillosis and pulmonary aspergillosis without tracheobronchial lesions